Caris Life Sciences
186 hedge funds and large institutions have $3.92B invested in Caris Life Sciences in 2025 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 63 increasing their positions, 30 reducing their positions, and 27 closing their positions.
185% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 27
184% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $5.09M
110% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 30
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
35% more funds holding
Funds holding: 138 → 186 (+48)
15% more capital invested
Capital invested by funds: $3.41B → $3.92B (+$507M)
11.18% more ownership
Funds ownership: 40.33% → 51.5% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$129M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$87.7M |
| 3 |
PC
PointState Capital
New York
|
+$79.8M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$54.9M |
| 5 |
BlackRock
New York
|
+$48.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLG
Silver Lake Group
Menlo Park,
California
|
-$160M |
| 2 |
SSP
Sixth Street Partners
Dallas,
Texas
|
-$141M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$59.1M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$33.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$33.3M |
CAI Hedge Fund Activity: Q4 2025 in Review
186 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Caris Life Sciences (CAI) for Q4 2025, worth a combined $3.92B — up 15% from $3.41B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new CAI positions and 27 closed out — a net gain of 50 holders — while 63 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $129M. The largest seller was Silver Lake Group, exiting entirely with an estimated $160M sold.
- 186 institutional investors held Caris Life Sciences (CAI) as of Q4 2025, up from 138 in Q3 2025.
- Funds reported $3.92B of Caris Life Sciences stock for Q4 2025, up 15% quarter-over-quarter.
- 77 funds opened new Caris Life Sciences positions in Q4 2025 and 27 closed out, a net change of +50 holders.
- The largest Caris Life Sciences buyer in Q4 2025 was Fidelity Investments, an estimated $129M added.
- The largest Caris Life Sciences seller in Q4 2025 was Silver Lake Group, an estimated $160M sold.
Based on aggregated 13F filings for Q4 2025.